Literature DB >> 8122117

Rheumatic manifestations of hepatitis C infection.

L B Siegel1, L Cohn, D Nashel.   

Abstract

With the advent of serological testing for the hepatitis C virus (HCV) clinicians can better recognize disorders associated with a subset of non-A, non-B hepatitis. As with hepatitis A and B virus infections, HCV disease may be associated with arthritis. Three patients with atypical arthritis who were subsequently discovered to have HCV infection are described. HCV infection should be considered in the differential diagnosis in patients with atypical arthritis.

Entities:  

Mesh:

Year:  1993        PMID: 8122117     DOI: 10.1016/s0049-0172(05)80035-6

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  5 in total

1.  Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection.

Authors:  Jillian Kallman; Mary Margaret O'Neil; Brett Larive; Navdeep Boparai; Leonard Calabrese; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

2.  Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection.

Authors:  Y H Lee; J D Ji; J E Yeon; K S Byun; C H Lee; G G Song
Journal:  Ann Rheum Dis       Date:  1998-12       Impact factor: 19.103

3.  Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases.

Authors:  C A von Mühlen; E K Chan; C L Peebles; H Imai; K Kiyosawa; E M Tan
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

4.  [Viral arthritides].

Authors:  E Märker-Hermann; N Schütz; H Bauer
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.530

5.  Multiplex cytokine profiling of initial therapeutic response in patients with chronic hepatitis C virus infection.

Authors:  Harlan Wright; Philip Alex; Thuan Nguyen; Teddy Bader; Ahmet Gurakar; Anthony Sebastian; Liberty Gonzales; Gemma Wallis; Mark Naylor; Igor Dozmorov; Michael Centola; Bakr Nour
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.